Influenza A virus, split virion
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2008
- First approval year
- 2008
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Influenza A virus, split virion
- Adjupanrix (previously pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals)
- adjupanrix previously pandemic influenza vaccine h5n1 split virion inactivated adjuvanted glaxosmithkline biologicals
- arepanrix
- Arepanrix
- humenza
- Humenza
- influenza a virus split virion component of idflu
- influenza a virus split virion component of intanza
- Influenza a virus, split virion component of idflu
- Influenza a virus, split virion component of intanza
- pandemrix
- Pandemrix
- Prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals
- prepandemic influenza vaccine h5n1 split virion inactivated adjuvanted glaxosmithkline biologicals
- prepandrix
- Prepandrix
- pumarix
- Pumarix
- 15 mcg h5n1 stored as monobulk
- 7 5 mcg h5n1 stored as monobulk
- 90 mcg H5N1 (stored in vials)
- 90 mcg h5n1 stored as monobulk
- 90 mcg h5n1 stored in vials
- a h5n1 inactivated influenza vaccine iiv
- A(H5N1) inactivated influenza vaccine (IIV)
- arepanrix
- Arepanrix
- Arepanrix®
- Arepanrix™
- h5n1
- H5N1
- H5N1 vaccine (Arepanrix)
- h5n1 vaccine arepanrix
- Influenza A (H5N1) Virus monovalent vaccine
- Influenza A (H5N1) Virus Monovalent Vaccine
- Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).
- influenza a h1n1 2009 as03 adjuvanted pandemrix
- influenza a h5n1
- influenza a h5n1 virus monovalent vaccine
- influenza a h5n1 virus monovalent vaccine adjuvanted
- influenza a h5n1 virus monovalent vaccine gsk1557484a
- influenza a virus split virion
- Influenza a virus, split virion
And 29 more, listed on the interactive page.
- ChEMBL ID
- CHEMBL6068363
- First in class
- No
- Orphan designation
- No
- Drug name stem
- vir-
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- Influenza, Human
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007328
- Subject identifier
- D007251
- Condition identifier
- EFO_0007248
- Condition identifier
- EFO_0007328
- Condition identifier
- EFO_0007411
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004980
- Condition identifier
- MONDO_0005109
- Condition identifier
- MONDO_0005114
- Condition identifier
- MONDO_0005404
- Condition identifier
- MONDO_0005494
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005546
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005608
- Condition identifier
- MONDO_0005812
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008170
- Condition identifier
- MONDO_0008383
- Condition identifier
- MONDO_0100096
- Event
- anal fistula
- Reports
- 5
- Reporting signal score
- 13.7835
- Event
- anti-neutrophil cytoplasmic antibody positive vasculitis
- Reports
- 4
- Reporting signal score
- 12.4258
- Event
- areflexia
- Reports
- 4
- Reporting signal score
- 11.5848
- Event
- asthma
- Reports
- 25
- Reporting signal score
- 43.4913
- Event
- atrial septal defect
- Reports
- 5
- Reporting signal score
- 9.33042
- Event
- blood pressure increased
- Reports
- 14
- Reporting signal score
- 12.4548
- Event
- blood pressure systolic increased
- Reports
- 7
- Reporting signal score
- 12.9985
- Event
- bronchiectasis
- Reports
- 5
- Reporting signal score
- 12.2729
- Event
- burns second degree
- Reports
- 5
- Reporting signal score
- 20.6639
- Event
- chills
- Reports
- 19
- Reporting signal score
- 21.6615
- Event
- chronic obstructive pulmonary disease
- Reports
- 55
- Reporting signal score
- 174.427
- Event
- congenital arterial malformation
- Reports
- 2
- Reporting signal score
- 9.08409
- Event
- congenital hiatus hernia
- Reports
- 2
- Reporting signal score
- 13.2168
- Event
- congenital pulmonary hypertension
- Reports
- 2
- Reporting signal score
- 9.69002
- Event
- congenital tricuspid valve incompetence
- Reports
- 3
- Reporting signal score
- 15.3477
- Event
- coordination abnormal
- Reports
- 6
- Reporting signal score
- 12.3111
- Event
- cough
- Reports
- 18
- Reporting signal score
- 9.39101
- Event
- crying
- Reports
- 6
- Reporting signal score
- 8.92887
- Event
- csf immunoglobulin increased
- Reports
- 1
- Reporting signal score
- 7.6546
- Event
- diabetic neuropathy
- Reports
- 6
- Reporting signal score
- 19.6923
- Event
- drug hypersensitivity
- Reports
- 36
- Reporting signal score
- 33.357
- Event
- dyspnoea
- Reports
- 44
- Reporting signal score
- 26.6004
- Event
- electronystagmogram abnormal
- Reports
- 1
- Reporting signal score
- 10.9503
- Event
- encephalitis autoimmune
- Reports
- 3
- Reporting signal score
- 10.4985
- Event
- exposure to communicable disease
- Reports
- 3
- Reporting signal score
- 12.3028
And 49 more, listed on the interactive page.
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (109)
- A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine
- A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months
- A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study
- A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults
- A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older
- A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults
- A Study of Influenza Virus Vaccines in Children and Adults
- A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older
- Afluria Pregnancy Registry
- Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 08/09 Season.
- Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 09/10 Season
- Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010/2011 Season
- Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2012/2013 Season
- Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season
- Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults
- Assessment of Safety and Immunogenicity of Intradermal Unadjuvanted Portion of Pandemrix® Via a Microneedle Device With Intramuscular Adjuvanted Pandemrix® as Reference
- Cell Mediated Immunity in Older Adults
- Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older
- Clinical Trial of Inactivated Influenza Vaccine (0.5ml Formulation)
- Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)
Approved for (1)
In development for (3)
- Breast cancer Phase 1
- Colorectal cancer Phase 2
- Triple-negative breast carcinoma Phase 1
Other linked conditions (9)
- Atopic eczema
- COVID-19
- Fibromyalgia
- HIV infectious disease
- Myalgic encephalomeyelitis/chronic fatigue syndrome
- Ovarian cancer
- Pneumococcal infection
- Rheumatoid arthritis
- Varicella zoster infection